Form D · Biotechnology
Nanochon, Inc.
Washington, DC · CIK 0001885962
Offering snapshot reported Feb 5, 2026 · SEC filing
- Reported sold
- $3.58M Offering amount: $4.22M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Dec 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 5, 2026 | Initial | $3,582,315 | No comparison | 39 | SEC filing |
| May 15, 2024 | Amendment | $3,991,279 | $2,189,998vs Aug 28, 2023 | 34 | SEC filing |
| Aug 28, 2023 | Initial | $1,801,281 | No comparison | 25 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-572475
Source: Form D, filed Feb 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sean Churchill | Director |
| Robert Creeden | Director |
| Benjamin Holmes | Director, Executive |
| Greg Horner | Director |
| Kurt Jacobus | Director |
| Nick Pachuda | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1317 Shepherd St Nw Unit D
Washington, DC, 20011
Washington, DC, 20011